BUSINESS

Hisamitsu’s Osteoarthritis Patch Drug Delivers Positive PII Data; PIII Launch Planned in FY2020

November 27, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japanese patch drug powerhouse Hisamitsu Pharmaceutical said on November 26 that its analgesic transdermal patch HP-5000 (diclofenac) delivered positive data in a PII clinical study conducted in the US for the treatment of osteoarthritis knee pain. The study demonstrated its…

To read the full story

Hisamitsu’s Osteoarthritis Patch Drug Fails in US PIII Study
October 31, 2022
Hisamitsu’s Osteoarthritis Patch Drug Enters PIII in US
January 6, 2021

BUSINESS

Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
Mochida Seeks Pediatric Expansion for Urece
July 2, 2026
Kowa Files US NDA for Nicox’s Glaucoma Drug
July 2, 2026
GNI Closes Acquisition of Ayumi Pharma
July 2, 2026
Toho to Acquire Ishin Pharma, Bring Allostem Distribution In-House
July 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Psychology of ‘Stuck’: Understanding Why Changing Jobs Feels So Hard

By Philip Carrigan

Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…